Lifecore Biomedical, Inc. (LFCR) Stock Competitors & Peer Comparison

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TAK has a market cap of 50.5B. Regarding current trading prices, LFCR is priced at $5.02, while TAK trades at $15.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TAK's P/E ratio is 42.04. In terms of profitability, LFCR's ROE is -1.47%, compared to TAK's ROE of +0.03%. Regarding short-term risk, LFCR is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check TAK's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TEVA has a market cap of 41.1B. Regarding current trading prices, LFCR is priced at $5.02, while TEVA trades at $35.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TEVA's P/E ratio is 26.36. In terms of profitability, LFCR's ROE is -1.47%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, LFCR is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check TEVA's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, HLN has a market cap of 40.2B. Regarding current trading prices, LFCR is priced at $5.02, while HLN trades at $9.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas HLN's P/E ratio is 18.12. In terms of profitability, LFCR's ROE is -1.47%, compared to HLN's ROE of +0.17%. Regarding short-term risk, LFCR is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check HLN's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, VTRS has a market cap of 18.9B. Regarding current trading prices, LFCR is priced at $5.02, while VTRS trades at $16.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas VTRS's P/E ratio is -54.20. In terms of profitability, LFCR's ROE is -1.47%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, LFCR is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check VTRS's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, LFCR is priced at $5.02, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ITCI's P/E ratio is -180.64. In terms of profitability, LFCR's ROE is -1.47%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, LFCR is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check ITCI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ELAN has a market cap of 11.9B. Regarding current trading prices, LFCR is priced at $5.02, while ELAN trades at $23.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ELAN's P/E ratio is -47.78. In terms of profitability, LFCR's ROE is -1.47%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, LFCR is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check ELAN's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, RGC has a market cap of 11.8B. Regarding current trading prices, LFCR is priced at $5.02, while RGC trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas RGC's P/E ratio is -2390.00. In terms of profitability, LFCR's ROE is -1.47%, compared to RGC's ROE of -2.32%. Regarding short-term risk, LFCR is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check RGC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, LFCR is priced at $5.02, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CTLT's P/E ratio is -27.84. In terms of profitability, LFCR's ROE is -1.47%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, LFCR is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check CTLT's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, RDY has a market cap of 11.3B. Regarding current trading prices, LFCR is priced at $5.02, while RDY trades at $13.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas RDY's P/E ratio is 25.70. In terms of profitability, LFCR's ROE is -1.47%, compared to RDY's ROE of +0.12%. Regarding short-term risk, LFCR is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check RDY's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, LFCR is priced at $5.02, while LNTH trades at $99.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas LNTH's P/E ratio is 23.70. In terms of profitability, LFCR's ROE is -1.47%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, LFCR is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check LNTH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, LFCR is priced at $5.02, while INDV trades at $36.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas INDV's P/E ratio is 18.47. In terms of profitability, LFCR's ROE is -1.47%, compared to INDV's ROE of -1.42%. Regarding short-term risk, LFCR is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check INDV's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, AMRX has a market cap of 4.2B. Regarding current trading prices, LFCR is priced at $5.02, while AMRX trades at $13.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas AMRX's P/E ratio is 35.59. In terms of profitability, LFCR's ROE is -1.47%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, LFCR is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check AMRX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, LFCR is priced at $5.02, while SUPN trades at $46.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SUPN's P/E ratio is -90.55. In terms of profitability, LFCR's ROE is -1.47%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, LFCR is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check SUPN's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, LFCR is priced at $5.02, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas DCPH's P/E ratio is -11.58. In terms of profitability, LFCR's ROE is -1.47%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, LFCR is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check DCPH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, LFCR is priced at $5.02, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, LFCR's ROE is -1.47%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, LFCR is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check AVDL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, BHC has a market cap of 2B. Regarding current trading prices, LFCR is priced at $5.02, while BHC trades at $5.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas BHC's P/E ratio is -1.65. In terms of profitability, LFCR's ROE is -1.47%, compared to BHC's ROE of +1.21%. Regarding short-term risk, LFCR is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check BHC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, HCM has a market cap of 2B. Regarding current trading prices, LFCR is priced at $5.02, while HCM trades at $11.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas HCM's P/E ratio is 4.32. In terms of profitability, LFCR's ROE is -1.47%, compared to HCM's ROE of +0.41%. Regarding short-term risk, LFCR is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check HCM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, LFCR is priced at $5.02, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas EMBCV's P/E ratio is N/A. In terms of profitability, LFCR's ROE is -1.47%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, LFCR is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check EMBCV's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, LFCR is priced at $5.02, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas DVAX's P/E ratio is -41.89. In terms of profitability, LFCR's ROE is -1.47%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, LFCR is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check DVAX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, LFCR is priced at $5.02, while ANIP trades at $78.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ANIP's P/E ratio is 20.08. In terms of profitability, LFCR's ROE is -1.47%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, LFCR is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ANIP's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, LFCR is priced at $5.02, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TARO's P/E ratio is 30.05. In terms of profitability, LFCR's ROE is -1.47%, compared to TARO's ROE of +0.03%. Regarding short-term risk, LFCR is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check TARO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, LFCR is priced at $5.02, while PRGO trades at $11.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas PRGO's P/E ratio is -0.83. In terms of profitability, LFCR's ROE is -1.47%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, LFCR is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check PRGO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, LFCR is priced at $5.02, while HROW trades at $35.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas HROW's P/E ratio is -92.66. In terms of profitability, LFCR's ROE is -1.47%, compared to HROW's ROE of -0.34%. Regarding short-term risk, LFCR is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check HROW's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, LFCR is priced at $5.02, while PAHC trades at $30.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas PAHC's P/E ratio is 13.21. In terms of profitability, LFCR's ROE is -1.47%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, LFCR is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check PAHC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, EVO has a market cap of 1.1B. Regarding current trading prices, LFCR is priced at $5.02, while EVO trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas EVO's P/E ratio is -4.87. In terms of profitability, LFCR's ROE is -1.47%, compared to EVO's ROE of -0.24%. Regarding short-term risk, LFCR is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check EVO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, LFCR is priced at $5.02, while COLL trades at $33.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas COLL's P/E ratio is 16.31. In terms of profitability, LFCR's ROE is -1.47%, compared to COLL's ROE of +0.27%. Regarding short-term risk, LFCR is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check COLL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CRON has a market cap of 1.1B. Regarding current trading prices, LFCR is priced at $5.02, while CRON trades at $2.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CRON's P/E ratio is -142.00. In terms of profitability, LFCR's ROE is -1.47%, compared to CRON's ROE of -0.00%. Regarding short-term risk, LFCR is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check CRON's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ALVO has a market cap of 1B. Regarding current trading prices, LFCR is priced at $5.02, while ALVO trades at $3.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ALVO's P/E ratio is 33.60. In terms of profitability, LFCR's ROE is -1.47%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, LFCR and ALVO have similar daily volatility (3.23).Check ALVO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, LFCR is priced at $5.02, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas PETQ's P/E ratio is 83.73. In terms of profitability, LFCR's ROE is -1.47%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, LFCR is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check PETQ's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, PCRX has a market cap of 913.4M. Regarding current trading prices, LFCR is priced at $5.02, while PCRX trades at $23.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas PCRX's P/E ratio is 178.62. In terms of profitability, LFCR's ROE is -1.47%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, LFCR is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check PCRX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, AMPH has a market cap of 831.2M. Regarding current trading prices, LFCR is priced at $5.02, while AMPH trades at $18.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas AMPH's P/E ratio is 11.36. In terms of profitability, LFCR's ROE is -1.47%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, LFCR is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check AMPH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TLRY has a market cap of 659M. Regarding current trading prices, LFCR is priced at $5.02, while TLRY trades at $5.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TLRY's P/E ratio is -0.38. In terms of profitability, LFCR's ROE is -1.47%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, LFCR is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check TLRY's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, IRWD has a market cap of 587.7M. Regarding current trading prices, LFCR is priced at $5.02, while IRWD trades at $3.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas IRWD's P/E ratio is 5.76. In terms of profitability, LFCR's ROE is -1.47%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, LFCR is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check IRWD's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, LFCR is priced at $5.02, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas BDSI's P/E ratio is 6.82. In terms of profitability, LFCR's ROE is -1.47%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, LFCR is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check BDSI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CGC has a market cap of 464.2M. Regarding current trading prices, LFCR is priced at $5.02, while CGC trades at $1.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CGC's P/E ratio is -0.81. In terms of profitability, LFCR's ROE is -1.47%, compared to CGC's ROE of -0.51%. Regarding short-term risk, LFCR is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check CGC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, KMDA has a market cap of 450.5M. Regarding current trading prices, LFCR is priced at $5.02, while KMDA trades at $7.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas KMDA's P/E ratio is 22.31. In terms of profitability, LFCR's ROE is -1.47%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, LFCR is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check KMDA's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, EOLS has a market cap of 432M. Regarding current trading prices, LFCR is priced at $5.02, while EOLS trades at $6.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas EOLS's P/E ratio is -9.94. In terms of profitability, LFCR's ROE is -1.47%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, LFCR is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check EOLS's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, AQST has a market cap of 399.2M. Regarding current trading prices, LFCR is priced at $5.02, while AQST trades at $4.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas AQST's P/E ratio is -6.59. In terms of profitability, LFCR's ROE is -1.47%, compared to AQST's ROE of +1.91%. Regarding short-term risk, LFCR is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check AQST's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SNDL has a market cap of 383.6M. Regarding current trading prices, LFCR is priced at $5.02, while SNDL trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SNDL's P/E ratio is -49.33. In terms of profitability, LFCR's ROE is -1.47%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, LFCR is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check SNDL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SIGA has a market cap of 335.7M. Regarding current trading prices, LFCR is priced at $5.02, while SIGA trades at $4.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SIGA's P/E ratio is 16.71. In terms of profitability, LFCR's ROE is -1.47%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, LFCR is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check SIGA's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ORGO has a market cap of 330.7M. Regarding current trading prices, LFCR is priced at $5.02, while ORGO trades at $2.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ORGO's P/E ratio is -21.42. In terms of profitability, LFCR's ROE is -1.47%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, LFCR is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ORGO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, LFCR is priced at $5.02, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ALIM's P/E ratio is 5.28. In terms of profitability, LFCR's ROE is -1.47%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, LFCR is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check ALIM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TKNO has a market cap of 289.5M. Regarding current trading prices, LFCR is priced at $5.02, while TKNO trades at $5.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TKNO's P/E ratio is -17.42. In terms of profitability, LFCR's ROE is -1.47%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, LFCR is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check TKNO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, LFCR is priced at $5.02, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas LNDC's P/E ratio is -4.04. In terms of profitability, LFCR's ROE is -1.47%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, LFCR is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check LNDC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, LFCR is priced at $5.02, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TYHT's P/E ratio is -1.61. In terms of profitability, LFCR's ROE is -1.47%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, LFCR is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check TYHT's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ACB has a market cap of 204.2M. Regarding current trading prices, LFCR is priced at $5.02, while ACB trades at $3.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ACB's P/E ratio is -3.33. In terms of profitability, LFCR's ROE is -1.47%, compared to ACB's ROE of -0.08%. Regarding short-term risk, LFCR is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check ACB's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, EMBC has a market cap of 199.9M. Regarding current trading prices, LFCR is priced at $5.02, while EMBC trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas EMBC's P/E ratio is 1.78. In terms of profitability, LFCR's ROE is -1.47%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, LFCR is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check EMBC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, LFCR is priced at $5.02, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas REPH's P/E ratio is -8.04. In terms of profitability, LFCR's ROE is -1.47%, compared to REPH's ROE of -0.22%. Regarding short-term risk, LFCR is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check REPH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, DERM has a market cap of 173.7M. Regarding current trading prices, LFCR is priced at $5.02, while DERM trades at $6.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas DERM's P/E ratio is -17.05. In terms of profitability, LFCR's ROE is -1.47%, compared to DERM's ROE of -0.36%. Regarding short-term risk, LFCR is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check DERM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, OGI has a market cap of 160.5M. Regarding current trading prices, LFCR is priced at $5.02, while OGI trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas OGI's P/E ratio is -7.12. In terms of profitability, LFCR's ROE is -1.47%, compared to OGI's ROE of -0.07%. Regarding short-term risk, LFCR is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check OGI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, LFCR is priced at $5.02, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas THTX's P/E ratio is -17.84. In terms of profitability, LFCR's ROE is -1.47%, compared to THTX's ROE of +0.47%. Regarding short-term risk, LFCR is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check THTX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ASRT has a market cap of 151.5M. Regarding current trading prices, LFCR is priced at $5.02, while ASRT trades at $23.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ASRT's P/E ratio is -4.22. In terms of profitability, LFCR's ROE is -1.47%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, LFCR is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check ASRT's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CRDL has a market cap of 136.5M. Regarding current trading prices, LFCR is priced at $5.02, while CRDL trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CRDL's P/E ratio is -4.36. In terms of profitability, LFCR's ROE is -1.47%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, LFCR is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check CRDL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, LFCR is priced at $5.02, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SCTL's P/E ratio is -7.86. In terms of profitability, LFCR's ROE is -1.47%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, LFCR is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check SCTL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, LFCR is priced at $5.02, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas PROC's P/E ratio is 1.53. In terms of profitability, LFCR's ROE is -1.47%, compared to PROC's ROE of -2.22%. Regarding short-term risk, LFCR is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check PROC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, LFCR is priced at $5.02, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas OPTN's P/E ratio is -4.42. In terms of profitability, LFCR's ROE is -1.47%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, LFCR is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check OPTN's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, LFCR is priced at $5.02, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ZOM's P/E ratio is -1.62. In terms of profitability, LFCR's ROE is -1.47%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, LFCR is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ZOM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CPIX has a market cap of 92.4M. Regarding current trading prices, LFCR is priced at $5.02, while CPIX trades at $6.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CPIX's P/E ratio is -12.59. In terms of profitability, LFCR's ROE is -1.47%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, LFCR is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check CPIX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, LFCR is priced at $5.02, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas GRVI's P/E ratio is 26.05. In terms of profitability, LFCR's ROE is -1.47%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, LFCR is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check GRVI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ALVOW has a market cap of 81.1M. Regarding current trading prices, LFCR is priced at $5.02, while ALVOW trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ALVOW's P/E ratio is N/A. In terms of profitability, LFCR's ROE is -1.47%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, LFCR is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ALVOW's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, LFCR is priced at $5.02, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, LFCR's ROE is -1.47%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, LFCR is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ZYNE's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, LFCR is priced at $5.02, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SSIC's P/E ratio is 11.93. In terms of profitability, LFCR's ROE is -1.47%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, LFCR is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check SSIC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, BGM has a market cap of 66.4M. Regarding current trading prices, LFCR is priced at $5.02, while BGM trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas BGM's P/E ratio is -1.14. In terms of profitability, LFCR's ROE is -1.47%, compared to BGM's ROE of -0.03%. Regarding short-term risk, LFCR is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check BGM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, INCR has a market cap of 65.6M. Regarding current trading prices, LFCR is priced at $5.02, while INCR trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas INCR's P/E ratio is -5.22. In terms of profitability, LFCR's ROE is -1.47%, compared to INCR's ROE of -0.09%. Regarding short-term risk, LFCR is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check INCR's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, LFCR is priced at $5.02, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas VLNS's P/E ratio is -1.03. In terms of profitability, LFCR's ROE is -1.47%, compared to VLNS's ROE of N/A. Regarding short-term risk, LFCR is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check VLNS's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, LFCR is priced at $5.02, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas DRRX's P/E ratio is -4.44. In terms of profitability, LFCR's ROE is -1.47%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, LFCR is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check DRRX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, LFCR is priced at $5.02, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas JUPW's P/E ratio is -2.41. In terms of profitability, LFCR's ROE is -1.47%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, LFCR is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check JUPW's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, LFCR is priced at $5.02, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas QLI's P/E ratio is -4.92. In terms of profitability, LFCR's ROE is -1.47%, compared to QLI's ROE of -0.16%. Regarding short-term risk, LFCR is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check QLI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ZYBT has a market cap of 38.6M. Regarding current trading prices, LFCR is priced at $5.02, while ZYBT trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ZYBT's P/E ratio is -3.70. In terms of profitability, LFCR's ROE is -1.47%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, LFCR is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ZYBT's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, IXHL has a market cap of 38.5M. Regarding current trading prices, LFCR is priced at $5.02, while IXHL trades at $3.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas IXHL's P/E ratio is -0.20. In terms of profitability, LFCR's ROE is -1.47%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, LFCR is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check IXHL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SCYX has a market cap of 35.5M. Regarding current trading prices, LFCR is priced at $5.02, while SCYX trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SCYX's P/E ratio is -1.47. In terms of profitability, LFCR's ROE is -1.47%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, LFCR is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check SCYX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, LFCR is priced at $5.02, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas HEXO's P/E ratio is -0.26. In terms of profitability, LFCR's ROE is -1.47%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, LFCR is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check HEXO's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, QNTM has a market cap of 30.8M. Regarding current trading prices, LFCR is priced at $5.02, while QNTM trades at $6.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas QNTM's P/E ratio is -0.89. In terms of profitability, LFCR's ROE is -1.47%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, LFCR is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check QNTM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, RMTI has a market cap of 29.3M. Regarding current trading prices, LFCR is priced at $5.02, while RMTI trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas RMTI's P/E ratio is -4.96. In terms of profitability, LFCR's ROE is -1.47%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, LFCR is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check RMTI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TXMD has a market cap of 24.8M. Regarding current trading prices, LFCR is priced at $5.02, while TXMD trades at $2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TXMD's P/E ratio is 214.00. In terms of profitability, LFCR's ROE is -1.47%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, LFCR is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check TXMD's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, LFCR is priced at $5.02, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CYTH's P/E ratio is -0.80. In terms of profitability, LFCR's ROE is -1.47%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, LFCR is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check CYTH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, OPTH has a market cap of 19.2M. Regarding current trading prices, LFCR is priced at $5.02, while OPTH trades at $5.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas OPTH's P/E ratio is -5.46. In terms of profitability, LFCR's ROE is -1.47%, compared to OPTH's ROE of -0.57%. Regarding short-term risk, LFCR is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check OPTH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, LFCR is priced at $5.02, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas EVOK's P/E ratio is -7.97. In terms of profitability, LFCR's ROE is -1.47%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, LFCR is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check EVOK's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, AYTU has a market cap of 18.5M. Regarding current trading prices, LFCR is priced at $5.02, while AYTU trades at $2.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas AYTU's P/E ratio is -0.49. In terms of profitability, LFCR's ROE is -1.47%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, LFCR is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check AYTU's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, TLPH has a market cap of 16.7M. Regarding current trading prices, LFCR is priced at $5.02, while TLPH trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas TLPH's P/E ratio is -2.91. In terms of profitability, LFCR's ROE is -1.47%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, LFCR is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check TLPH's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, LFCR is priced at $5.02, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ACRX's P/E ratio is -0.31. In terms of profitability, LFCR's ROE is -1.47%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, LFCR is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ACRX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, COSM has a market cap of 13.7M. Regarding current trading prices, LFCR is priced at $5.02, while COSM trades at $0.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas COSM's P/E ratio is -0.38. In terms of profitability, LFCR's ROE is -1.47%, compared to COSM's ROE of -0.96%. Regarding short-term risk, LFCR is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check COSM's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, BFRI has a market cap of 11.2M. Regarding current trading prices, LFCR is priced at $5.02, while BFRI trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas BFRI's P/E ratio is -0.90. In terms of profitability, LFCR's ROE is -1.47%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, LFCR is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check BFRI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, LFCR is priced at $5.02, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas AGRX's P/E ratio is -0.89. In terms of profitability, LFCR's ROE is -1.47%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, LFCR is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check AGRX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, LFCR is priced at $5.02, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas NLTX's P/E ratio is -0.28. In terms of profitability, LFCR's ROE is -1.47%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, LFCR is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check NLTX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, YCBD has a market cap of 8.1M. Regarding current trading prices, LFCR is priced at $5.02, while YCBD trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas YCBD's P/E ratio is 0.31. In terms of profitability, LFCR's ROE is -1.47%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, LFCR is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check YCBD's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, EGRX has a market cap of 7.6M. Regarding current trading prices, LFCR is priced at $5.02, while EGRX trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas EGRX's P/E ratio is 8.21. In terms of profitability, LFCR's ROE is -1.47%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, LFCR is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check EGRX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, LFCR is priced at $5.02, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas LCI's P/E ratio is -0.04. In terms of profitability, LFCR's ROE is -1.47%, compared to LCI's ROE of +1.66%. Regarding short-term risk, LFCR is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check LCI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, LFCR is priced at $5.02, while BGXX trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas BGXX's P/E ratio is -0.76. In terms of profitability, LFCR's ROE is -1.47%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, LFCR is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check BGXX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, LFCR is priced at $5.02, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ADMP's P/E ratio is -0.08. In terms of profitability, LFCR's ROE is -1.47%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, LFCR is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check ADMP's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, LFCR is priced at $5.02, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas MNK's P/E ratio is -0.44. In terms of profitability, LFCR's ROE is -1.47%, compared to MNK's ROE of -0.26%. Regarding short-term risk, LFCR is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check MNK's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, GELS has a market cap of 4.5M. Regarding current trading prices, LFCR is priced at $5.02, while GELS trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas GELS's P/E ratio is -0.94. In terms of profitability, LFCR's ROE is -1.47%, compared to GELS's ROE of -0.43%. Regarding short-term risk, LFCR is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check GELS's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, LFCR is priced at $5.02, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas FLGC's P/E ratio is -0.19. In terms of profitability, LFCR's ROE is -1.47%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, LFCR is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check FLGC's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, LFCR is priced at $5.02, while GHSI trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas GHSI's P/E ratio is -0.79. In terms of profitability, LFCR's ROE is -1.47%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, LFCR is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check GHSI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, RDHL has a market cap of 3.1M. Regarding current trading prices, LFCR is priced at $5.02, while RDHL trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas RDHL's P/E ratio is N/A. In terms of profitability, LFCR's ROE is -1.47%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, LFCR is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check RDHL's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, CPHI has a market cap of 2.6M. Regarding current trading prices, LFCR is priced at $5.02, while CPHI trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas CPHI's P/E ratio is -1.50. In terms of profitability, LFCR's ROE is -1.47%, compared to CPHI's ROE of -0.00%. Regarding short-term risk, LFCR is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check CPHI's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, LFCR is priced at $5.02, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas PLXP's P/E ratio is -0.22. In terms of profitability, LFCR's ROE is -1.47%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, LFCR is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check PLXP's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, LFCR is priced at $5.02, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas ATNX's P/E ratio is -0.02. In terms of profitability, LFCR's ROE is -1.47%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, LFCR is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for LFCR.Check ATNX's competition here

LFCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFCR stands at 188.3M. In comparison, SNOA has a market cap of 2M. Regarding current trading prices, LFCR is priced at $5.02, while SNOA trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFCR currently has a P/E ratio of -3.95, whereas SNOA's P/E ratio is -0.58. In terms of profitability, LFCR's ROE is -1.47%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, LFCR is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for LFCR.Check SNOA's competition here